Prosecution Insights
Last updated: April 19, 2026

Deciphera Pharmaceuticals LLC

4 pending office actions

Portfolio Summary

4
Total Pending OAs
2
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19308925 AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF TRAN, SUSAN T 1615 Final Rejection Aug 25, 2025
18464519 METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS VALENROD, YEVGENY 1628 Non-Final OA Sep 11, 2023
18078269 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF ENGLISH, CONNOR KENNEDY 1625 Non-Final OA Dec 09, 2022
17845275 USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA RODRIGUEZ, RAYNA B 1628 Final Rejection Jun 21, 2022

Managing Deciphera Pharmaceuticals LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month